Sinopharm Group Co Ltd
HKEX:1099
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
16.06
23.55
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Sinopharm Group Co Ltd
Sinopharm Group Co Ltd
Cash from Operating Activities
Sinopharm Group Co Ltd
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Sinopharm Group Co Ltd
HKEX:1099
|
Cash from Operating Activities
¥19.5B
|
CAGR 3-Years
21%
|
CAGR 5-Years
62%
|
CAGR 10-Years
13%
|
|
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
Cash from Operating Activities
¥5.7B
|
CAGR 3-Years
8%
|
CAGR 5-Years
6%
|
CAGR 10-Years
17%
|
|
|
Jointown Pharmaceutical Group Co Ltd
SSE:600998
|
Cash from Operating Activities
¥1.3B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
|
C
|
China National Medicines Corp Ltd
SSE:600511
|
Cash from Operating Activities
¥1.7B
|
CAGR 3-Years
13%
|
CAGR 5-Years
8%
|
CAGR 10-Years
17%
|
|
|
Huadong Medicine Co Ltd
SZSE:000963
|
Cash from Operating Activities
¥4.2B
|
CAGR 3-Years
5%
|
CAGR 5-Years
22%
|
CAGR 10-Years
12%
|
|
|
C
|
China National Accord Medicines Corp Ltd
SZSE:000028
|
Cash from Operating Activities
¥2.8B
|
CAGR 3-Years
43%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
Sinopharm Group Co Ltd
Glance View
Sinopharm Group Co., Ltd., a colossal force in China’s healthcare sector, navigates a complex landscape with the precision and might one might expect of a giant orchestrating a symphony. As the largest distributor of pharmaceutical and healthcare products in China, Sinopharm operates through a broad network, ensuring that life-saving drugs and medical devices seamlessly reach hospitals, clinics, and pharmacies across the nation. Their business thrives by acting as an intermediary, efficiently bridging the gap between countless pharmaceutical manufacturers and healthcare facilities. By managing this extensive logistics and distribution network, Sinopharm not only commands an influential position in the supply chain but also shapes the very infrastructure upon which China's healthcare system depends. With a vast catalog spanning essential medicines, traditional Chinese remedies, and modern medical equipment, Sinopharm generates revenue predominantly through the distribution margins on these products. Beyond its distribution prowess, Sinopharm has strategically expanded upstream and downstream within the healthcare industry. Diversification plays a key role in its business model as the company delves into pharmaceutical manufacturing, health services, and even healthcare logistics. By owning manufacturing facilities, Sinopharm is able to create a closed-loop system for certain medications, capitalizing on the entire value chain from production to retail. Furthermore, the group expands its influence through partnerships and acquisitions, carving out a robust presence in healthcare-related services, research, and development, and retail pharmacies. This multifaceted approach enables Sinopharm to fortify its profitability, reduce dependency on external entities, and enhance its resilience amidst fluctuations in the healthcare landscape. Through its expansive reach and innovative strategy, Sinopharm cements its status as a vital player in both the national and global healthcare arenas.
See Also
What is Sinopharm Group Co Ltd's Cash from Operating Activities?
Cash from Operating Activities
19.5B
CNY
Based on the financial report for Jun 30, 2024, Sinopharm Group Co Ltd's Cash from Operating Activities amounts to 19.5B CNY.
What is Sinopharm Group Co Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
13%
Over the last year, the Cash from Operating Activities growth was 63%. The average annual Cash from Operating Activities growth rates for Sinopharm Group Co Ltd have been 21% over the past three years , 62% over the past five years , and 13% over the past ten years .
You don't have any saved screeners yet